Clinical considerations for biosimilar antibodies

European Journal of Cancer, Supplement

Volumn 11, Issue 3, 2013, Pages 1-11

  Mellstedt, Håkan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biologic; Biosimilar; Extrapolation; Immunogenicity; Monoclonal antibody; Pharmacoeconomics; Pharmacovigilance

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; BEVACIZUMAB; BIOSIMILAR AGENT; CETUXIMAB; ERYTHROPOIETIN; ETANERCEPT; GLYCERYL TRINITRATE; HUMAN GROWTH HORMONE; INFLIXIMAB; METHOTREXATE; NIVESTIME; PALIVIZUMAB; RATIOGRASTIME; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; ANKYLOSING SPONDYLITIS; ANTIBODY STRUCTURE; ARTICLE; BIOLOGICAL THERAPY; BLOOD AUTOTRANSFUSION; BREAST CANCER; BREAST METASTASIS; CHRONIC KIDNEY FAILURE; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG QUALITY; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; ENTERITIS; FEASIBILITY STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; LARGE CELL LYMPHOMA; MOLECULAR WEIGHT; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT SAFETY; PITUITARY DWARFISM; PRACTICE GUIDELINE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; STOMACH CANCER; TURNER SYNDROME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84890242549     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/S1359-6349(13)70001-6     Document Type: Article

References (69)

1. Revers L, Furczon E An introduction to biologics and biosimilars. Part II: Subsequent entry biologics: biosame or biodifferent?. Can Pharmacists J 2010, 143:184-191.
2. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues 2012, Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
3. Weise M, Bielsky MC, De Smet K, et al. Biosimilars-why terminology matters. Nat Biotechnol 2011, 29:691-693.
4. Inflectra summary of opinion (initial authorisation) 2013, Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
5. Remsima summary of opinion (initial authorisation) 2013, Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
6. European Medicines Agency Guidelines on similar biological medicinal products 2005, Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
7. European Medicines Agency European public assessment reports: Biosimilars (accessed October 2013). http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d125&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit.
8. Schneider CK, Kalinke U Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008, 26:985-990.
9. Schellekens H Follow-on biologics: Challenges of the 'next generation'. Nephrol Dial Transplant 2005, 20:iv31-iv36.
10. Revers L, Furczon E An introduction to biologics and biosimilars. Part I: Biologics: What are they and where do they come from?. Can Pharmacists J 2010, 143:134-139.
11. Hu S, Dovichi NJ Capillary electrophoresis for the analysis of biopolymers. Anal Chem 2002, 74:2833-2850.
12. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M Physiochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013, 27:495-507.
13. López Garcia F, Zahn R, Riek R, Wüthrich K NMR structure of the bovine prion protein. Proc Natl Acad Sci U S A 2000, 97:8334-8339.
14. European Medicines Agency Product approvals (accessed October 30, 2013). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125.
15. Celltrion Healthcare Biosimilar development candidates (accessed October 30, 2013). http://www.celltrion.com/en/BIO/bio02.asp?menu_num=2.
16. EU Clinical Trials Register Biosimilar clinical trials (accessed October 30, 2013). https://www.clinicaltrialsregister.eu/.
17. Young-Hyuck I, Odarchenko P, Grecea D, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol 2013, 31(Suppl). Abstract 629.
18. Schneider CK, Vleminckx C, Gravanis I, et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 2012, 30:1179-1185.
19. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann Rheum Dis 2013, 72:1605-1612.
20. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.
21. Siegel JP. EMEA Workshop on Biosimilar Monoclonal Antibodies session 3: Clinical issues. Presented at EMEA Workshop on Biosimilar Monoclonal Antibodies, July 2, 2009, London, United Kingdom.
22. MabThera (rituximab) [package insert] 2013, Roche Products Limited, Welwyn Garden City, United Kingdom.
23. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: What clinicians should know. Blood 2012, 120:5111-5117.
24. Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: Position of the World Marrow Donor Association. Haematologica 2011, 96:942-947.
25. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1. J Biol Chem 2004, 279:32269-32274.
26. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A 2012, 109:6181-6186.
27. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
28. Vitolo U, Ladetto M, Boccomini C, et al. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol 2013, 31:3351-3359.
29. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet Oncol 2013, 14:525-533.
30. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013, 381:1817-1826.
31. Shitara K, Matsuo K, Muro K, Doi T, Ohtsu A Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer 2013 Jun 5, [Epub ahead of print].
32. Herceptin® (trastuzumab) [package insert] 2013, Roche Products Limited, Welwyn Garden City, United Kingdom.
33. Danese S, Gomollon F, on behalf of the Governing Board and Operational Board of ECCO ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013, 7:586-589.
34. ABPI position on biosimilar medicines 2013, The Association of the British Pharmaceuticals Industry, London, United Kingdom.
35. McCamish M, Woollett G The continuum of comparability extends to biosimilarity: How much is enough and what clinical data are necessary?. Clin Pharmacol Ther 2013, 93:315-317.
36. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011, 29:310-312.
37. Sundaram S, Matathia A, Qian J, et al. An innovative approach for the characterization of the isoforms of a monoclonal antibody product. MAbs 2011, 3:505-512.
38. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use 2012, Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
39. Xie H, Charkraborty A, Ahn J, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010, 2:379-394.
40. Rademacher TW, Parekh RB, Dwek RA Glycobiology. Annu Rev Biochem 1988, 57:785-838.
41. Schellekens H Biosimilar epoetins: how similar are they?. Eur J Hosp Pharm 2004, 3:243-247.
42. Sburlati AR, Umana P, Prati EG, Bailey JE Synthesis of bisected glycoforms of recombinant IFN-β by overexpression of β-1,4-N-acetylglucosaminyltransferase III in Chinese hamster ovary cells. Biotechnol Prog 1998, 14:189-192.
43. Liu DY, Chen X, Zhang-van Enk J, Plant M, Dillon TM, Flynn GC Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008, 283:29266-29272.
44. Robinson NE Protein deamidation. Proc Natl Acad Sci USA 2002, 99:5283-5288.
45. Schmelzer AE, Miller WM Hyperosmotic stress and elevated pCO2 alter monoclonal antibody charge distribution and monosaccharide content. Biotechnol Prog 2002, 18:346-353.
46. van den Hamer CJA, Morell AG, Scheinberg IH, Hickman J, Ashwell G Physical and chemical studies on ceruloplasmin: IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation. J Biol Chem 1970, 245:4397-4402.
47. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
48. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
49. Casadevall N, Eckardt KU, Rossert J Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005, 16(Suppl 1):S67-S69.
50. Jahn EM, Schneider CK How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. N Biotechnol 2009, 25:280-286.
51. Remicade® (infliximab) Summary of product characteristics (accessed October 2013). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf.
52. Annex to guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: guidance on similar medicinal products containing somatropin 2006, Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
53. Guideline on pharmacovigilance practices (GVP): module X - additional monitoring 2013, Heads of Medicines Agencies, European Medicines Agency, London, United Kingdom.
54. Guideline on pharmacovigilance practices (GVP): module V - risk management systems 2012, Heads of Medicines Agencies, European Medicines Agency, London, United Kingdom.
55. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins 2008, Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
56. Medicines and Healthcare Products Regulatory Agency Black Triangle Scheme - new medicines and vaccines subject to EU-wide additional monitoring Accessed October 2013. http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/BlackTriangleproducts/index.htm.
57. WHO informal consultation on international nonproprietary names (INN) policy for biosimilar products 2006, World Health Organization, Geneva, Switzerland.
58. Medicines and Healthcare Products Regulatory Agency Biosimilar products. Drug Saf Update 2008, 1:8.
59. Niederwieser D, Schmitz S Biosimilar agents in oncology/haematology: From approval to practice. Eur J Haematol 2011, 86:277-288.
60. Kermani F The German biosimilars breakthrough that never was (accessed October 2013). http://invivoblog.blogspot.com/2011/10/german-biosimilars-breakthrough-that.html.
61. Generics and Biosimilars Initiative Greece says no to automatic substitution of biologicals (accessed October 2013). http://gabionline.net/Biosimilars/News/Greece-says-no-to-automatic-substitution-of-biologicals.
62. Czech Society of Oncology Opinion of the Czech Society of Oncology on the possibility of biosimilar substitution (accessed October 2013). http://www.linkos.cz/press-releases/opinion-of-the-czech-society-for-oncology-on-the-possibility-of-biosimilar-substitution/.
63. Baumgartel C Austria increases dialogue in order to involve physicians more with biosimilars. GaBI Journal 2013, 2:8.
64. Cohen M, Morrow T, Penna P Managing the expanded use of biologics across therapeutic areas: An example from B-cell targeted therapies. Am J Manage Care 2006, 12:S24-S37.
65. Simoens S Biosimilar medicines and cost-effectiveness. Clinicoeconom Outcomes Res 2011, 3:29-36.
66. Vision 2015 2010, European Generic Medicines Association, Brussels, Belgium.
67. Grabowski H, Cockburn I, Long G The market for follow-on biologics: How will it evolve?. Health Aff (Millwood) 2006, 25:1291-1301.
68. King DR, Kanavos P Encouraging the use of generic medicines: Implications for transition economies. Croatian Med J 2002, 43:462-469.
69. Morelli G IMS Institute for Healthcare Informatics: biosimilars: evolution and trends (accessed October 2013). http://share.pdfonline.com/715d4c29076b42ac83589ca85c3213f1/Gabriel%20Morelli%2012%20febrero%202013.htm.